Literature DB >> 26993424

Midcingulate cortex: Structure, connections, homologies, functions and diseases.

Brent A Vogt1.   

Abstract

Midcingulate cortex (MCC) has risen in prominence as human imaging identifies unique structural and functional activity therein and this is the first review of its structure, connections, functions and disease vulnerabilities. The MCC has two divisions (anterior, aMCC and posterior, pMCC) that represent functional units and the cytoarchitecture, connections and neurocytology of each is shown with immunohistochemistry and receptor binding. The MCC is not a division of anterior cingulate cortex (ACC) and the "dorsal ACC" designation is a misnomer as it incorrectly implies that MCC is a division of ACC. Interpretation of findings among species and developing models of human diseases requires detailed comparative studies which is shown here for five species with flat maps and immunohistochemistry (human, monkey, rabbit, rat, mouse). The largest neurons in human cingulate cortex are in layer Vb of area 24 d in pMCC which project to the spinal cord. This area is part of the caudal cingulate premotor area which is involved in multisensory orientation of the head and body in space and neuron responses are tuned for the force and direction of movement. In contrast, the rostral cingulate premotor area in aMCC is involved in action-reinforcement associations and selection based on the amount of reward or aversive properties of a potential movement. The aMCC is activated by nociceptive information from the midline, mediodorsal and intralaminar thalamic nuclei which evoke fear and mediates nocifensive behaviors. This subregion also has high dopaminergic afferents and high dopamine-1 receptor binding and is engaged in reward processes. Opposing pain/avoidance and reward/approach functions are selected by assessment of potential outcomes and error detection according to feedback-mediated, decision making. Parietal afferents differentially terminate in MCC and provide for multisensory control in an eye- and head-centric manner. Finally, MCC vulnerability in human disease confirms the unique organization of MCC and supports the predictive validity of the MCC dichotomy. Vulnerability of aMCC is shown in chronic pain, obsessive-compulsive disorder with checking symptoms and attention-deficit/hyperactivity disorder and methylphenidate and pain medications selectively impact aMCC. In contrast, pMCC vulnerabilities are for progressive supranuclear palsy, unipolar depression and posttraumatic stress disorder. Thus, there is an emerging picture of the organization, functions and diseases of MCC. Future work will take this type of modular analysis to individual areas of which there are at least 10 in MCC.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognition; Comparative neuroanatomy; Insula; Neurocytology; Neurofilament proteins; Obsessive-compulsive disorder; Pain; Parietal; Primate

Mesh:

Substances:

Year:  2016        PMID: 26993424     DOI: 10.1016/j.jchemneu.2016.01.010

Source DB:  PubMed          Journal:  J Chem Neuroanat        ISSN: 0891-0618            Impact factor:   3.052


  114 in total

1.  Regional growth trajectories of cortical myelination in adolescents and young adults: longitudinal validation and functional correlates.

Authors:  Dongjin Kwon; Adolf Pfefferbaum; Edith V Sullivan; Kilian M Pohl
Journal:  Brain Imaging Behav       Date:  2020-02       Impact factor: 3.978

2.  Brain network profiling defines functionally specialized cortical networks.

Authors:  Simone Di Plinio; Sjoerd J H Ebisch
Journal:  Hum Brain Mapp       Date:  2018-08-04       Impact factor: 5.038

3.  Sensory processes modulate differences in multi-component behavior and cognitive control between childhood and adulthood.

Authors:  Krutika Gohil; Annet Bluschke; Veit Roessner; Ann-Kathrin Stock; Christian Beste
Journal:  Hum Brain Mapp       Date:  2017-06-28       Impact factor: 5.038

4.  Differential functional patterns of the human posterior cingulate cortex during activation and deactivation: a meta-analytic connectivity model.

Authors:  Jessica N Busler; Julio A Yanes; Ryan T Bird; Meredith A Reid; Jennifer L Robinson
Journal:  Exp Brain Res       Date:  2019-07-10       Impact factor: 1.972

5.  Dorsal anterior cingulate cortex and the value of control.

Authors:  Amitai Shenhav; Jonathan D Cohen; Matthew M Botvinick
Journal:  Nat Neurosci       Date:  2016-09-27       Impact factor: 24.884

Review 6.  The anterior midcingulate cortex might be a neuronal substrate for the ideomotor mechanism.

Authors:  T Michelet; A Badets
Journal:  Exp Brain Res       Date:  2021-06-29       Impact factor: 1.972

7.  Structural and functional brain signatures of endurance runners.

Authors:  Long Cao; Yuanchao Zhang; Ruiwang Huang; Lunxiong Li; Fengguang Xia; Liye Zou; Qian Yu; Jingyuan Lin; Fabian Herold; Stephane Perrey; Patrick Mueller; Milos Dordevic; Paul D Loprinzi; Yue Wang; Yudan Ma; Hongfa Zeng; Sicen Qu; Jinlong Wu; Zhanbing Ren
Journal:  Brain Struct Funct       Date:  2020-11-07       Impact factor: 3.270

8.  Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study.

Authors:  Ryosuke Tarumi; Sakiko Tsugawa; Yoshihiro Noda; Eric Plitman; Shiori Honda; Karin Matsushita; Sofia Chavez; Kyosuke Sawada; Masataka Wada; Mie Matsui; Shinya Fujii; Takahiro Miyazaki; M Mallar Chakravarty; Hiroyuki Uchida; Gary Remington; Ariel Graff-Guerrero; Masaru Mimura; Shinichiro Nakajima
Journal:  Neuropsychopharmacology       Date:  2019-12-16       Impact factor: 7.853

9.  The cingulate cortex: divided in pain.

Authors:  Thomas Nevian
Journal:  Nat Neurosci       Date:  2017-10-26       Impact factor: 24.884

10.  Increased on-state cortico-mesencephalic functional connectivity in Parkinson disease with freezing of gait.

Authors:  Daniel H Lench; Aaron Embry; Alyssa Hydar; Colleen A Hanlon; Gonzalo Revuelta
Journal:  Parkinsonism Relat Disord       Date:  2020-02-19       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.